News
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Anteris Technologies.
RELATED STOCKHEAD STORIES
Health & Biotech
Anteris Technologies is leading a heart condition treatment revolution
Health & Biotech
FDA submission looms as Artrya’s AI platform aims to capture the huge cardio diseases market
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: It certainly wasn’t cricket as Monday markets in Australia knocked right back to last year
Health & Biotech
Move over Neuren – Bioshares reckons these ASX health stocks could pop with upcoming key catalysts
Health & Biotech
ASX Health Stocks: Anteris successfully implants aortic valve, MGC Pharma a step closer to FDA submission
Health & Biotech
ASX Health Stocks: Cyclopharm confident after US FDA inspection; Anteris a step closer to FDA approval
News
Market Highlights: European blue chips at 15-year high, Aussie big four banks face headwinds, says fundie
Health & Biotech
ASX Health Stocks: Anteris’ 3D heart valve shows consistent results; as Nyrada announces a new lead drug
Health & Biotech
ASX Health Stocks: Rhythym Bio skyrockets 70pc after being granted UK CA Mark
Health & Biotech
ASX Health Stocks: Control Bionics launches world’s first autonomous driving wheelchair, DROVE
Health & Biotech
ScoPo’s Powerplays: ASX health stocks fall but cap raises show money flowing into sector
Health & Biotech
ASX Health Stocks: Argenica rockets by 30pc after showing potential breakthrough on Alzheimer’s
News
CLOSING BELL: RBA delivers Lowe voltage shock with ‘more now, and more to come’ interest rate call
News
CLOSING BELL: Adani and The Crown go head-to-head to see who can lose the most face in one day
Experts
After scaring everyone in 2022 it looks like ASX health stocks will have a pulse in 2023
Health & Biotech